Jennifer S. Buell PhD

Jennifer Buell, Ph.D. serves as the President & Chief Operating Officer and is responsible for organizational operations, including Research, Clinical Development, Manufacturing, Commercial Operations, Communications, Investor Relations, and External Affairs. Since joining Agenus in 2013, Dr. Buell has served as the Head of Global R&D operations, Head of Research, and Chief Communications and External Affairs Officer. During her tenure, she helped advance the expansion of Agenus from a neoantigen vaccine company to a global, fully-integrated platform company with a unique pipeline of immune-modulating antibodies, cancer vaccines, adjuvants, and adoptive cell therapies. With 20 years of biopharmaceutical R&D experience, Dr. Buell has extensive knowledge in advancing discovery candidates through development and experience communicating with external stakeholders including regulators, investors, and collaborators.

Jennifer Buell has a proven record of success in R&D leadership, most recently at Agenus, where she led high-performing teams in advancing candidates into the clinic and delivered on key alliance collaborations. Prior to joining Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and later was responsible for Program and Alliance Management at Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. Dr. Buell obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an MS in Biostatistics from Tufts University in Boston.